---
title: "Half-Dose Ticagrelor Monotherapy Versus Standard Dual Antiplatelet Therapy in Chronic Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized Pilot Trial With PRU-Guided Pharmacodynamic Assessment"
id: "medrxiv-19-half-dose-ticagrelor-monotherapy-versus-standard-dual-antiplatelet-therapy-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-half-dose-ticagrelor-monotherapy-versus-standard-dual-antiplatelet-therapy-in"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.06.29.26356433v1?rss=1"
published_at: "2026-07-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Half-Dose Ticagrelor Monotherapy Versus Standard Dual Antiplatelet Therapy in Chronic Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized Pilot Trial With PRU-Guided Pharmacodynamic Assessment
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-half-dose-ticagrelor-monotherapy-versus-standard-dual-antiplatelet-therapy-in
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.06.29.26356433v1?rss=1)
- **Published At:** 2026-07-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
Background: Aspirin-free P2Y12-inhibitor monotherapy after percutaneous coronary intervention (PCI) is an alternative to dual antiplatelet therapy (DAPT), but the evidence rests largely on full-dose ticagrelor in acute coronary syndrome and on designs retaining a DAPT run-in; East-Asian patients may not require the same antithrombotic intensity. We compared standard DAPT, DAPT with half-dose ticagrelor, and aspirin-free half-dose ticagrelor monotherapy initiated on the day of PCI in chronic coronary syndrome (CCS). Methods: Sixty-one East-Asian patients with CCS scheduled for elective PCI were randomized 1:1:1 to Control (aspirin plus clopidogrel), Experimental A (aspirin plus ticagrelor 45 mg twice daily), or Experimental B (ticagrelor 45 mg monotherapy, aspirin discontinued at day 2). DAPT arms continued for six months; Experimental B continued indefinitely. P2Y12 reaction units (PRU) were measured at baseline and at a median of 17 days. Results: PRU reduction was three-fold greater in both ticagrelor arms than in Control ({Delta}PRU -188 and -181 versus -60.5; P<0.001), with no difference between ticagrelor arms (P=0.772).
## Clinical Analysis & Structured Key Points
medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 07 Jul 2026. The item focuses on Half-Dose Ticagrelor Monotherapy Versus Standard Dual Antiplatelet Therapy in Chronic Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized Pilot Trial With PRU-Guided Pharmacodynamic Assessment. Review the original article for the full source wording and details.
## Related Clinical Research

- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic.md)
- [Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials](https://medichelpline.com/clinical-feed/plos-medicine-19-early-aspirin-withdrawal-versus-dual-antiplatelet-therapy-in-high-risk-patients-after-percutaneous-coronary-intervention-meta-analysis-of-randomized-trials.md)
- [Dual antithrombotic therapy with potent antiplatelet inhibitors in AF and ACS — randomized trial](https://medichelpline.com/clinical-feed/nature-0-dual-antithrombotic-therapy-using-potent-antiplatelet-inhibitors-in-atrial.md)
- [Sex Differences in Acute Coronary Syndrome Presentation and Management in Brazilian EMS](https://medichelpline.com/clinical-feed/medrxiv-2-sex-based-differences-in-clinical-presentation-management-and-outcomes-of-acute.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.